![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Biopure gives new meaning to blood work. The company makes an artificial blood product based on bovine red blood cells to deliver oxygen to patients with acute blood loss, anemia, or who have had a stroke or a heart attack. Its Hemopure, for humans, and Oxyglobin, for dogs (already approved for veterinary use), are made of purified and processed cow blood, have a two-year shelf life, do not require blood typing, and release more oxygen than a blood transfusion. The blood products also are less viscous than red blood cells, allowing them to flow more easily through partially blocked or constricted blood vessels. Chairman and CEO Carl Rausch owns about 44% of the company. BioPure 11 Hurley St. Cambridge, MA 02141 Phone: 617-234-6500 Fax: 617-234-6505 Web Site: biopure.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |